Lexaria Bioscience Corp. (NASDAQ:LEXX) saw its shares stay steady in price Thursday. The global innovator in drug delivery platforms has been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan.
This is Lexaria’s third patent to be granted in Japan, entitled Lipophilic Active Agent Infused Compositions With Reduced Food Effect. This patent recognizes DehydraTECH’s ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently regardless of the presence of foods within the gastrointestinal system – the so-called “food effect”.
Delivering drugs more consistently into the bloodstream regardless of the presence of food in the GI is an important achievement in the quest for more reliable drug dosing.
This is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol. Lexaria has patents granted or patent applications progressing in countries around the world with aggregate populations of nearly four billion people and will report on further progress as information becomes available.
In additional news, Lexaria has submitted its briefing book to the U.S. Food and Drug Administration (“FDA”). The Company has no further requirements or deliverables related to the pre-Investigational New Drug (“IND”) meeting request announced in June. The FDA has provided a target date of July 30 for meeting or comments.
LEXX shares lost a penny first thing Thursday to $2.83.
Related Stories
